Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Newland

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Lancet (London, England)|October 1, 2023
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trialCatherine M Broome, Vickie McDonald, Yoshitaka Miyakawa, et al.
Lancet (London, England)|February 10, 2009
The Academy of Medical Royal Colleges' statement on clinical research in the UKCarol Black, Andy Adam, Sabaratnam Arulkumaran, et al.
British Journal of Haematology|November 24, 2016
A United Kingdom Immune Thrombocytopenia (ITP) Forum review of practice: thrombopoietin receptor agonistsJecko Thachil, Catherine Bagot, Charlotte Bradbury, et al.
Blood|January 31, 2013
Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working GroupFrancesco Rodeghiero, Marc Michel, Terry Gernsheimer, et al.
Lancet (London, England)|February 5, 2008
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trialDavid J Kuter, James B Bussel, Roger M Lyons, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Lancet (London, England)|October 1, 2023
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trialCatherine M Broome, Vickie McDonald, Yoshitaka Miyakawa, et al.
Lancet (London, England)|February 10, 2009
The Academy of Medical Royal Colleges' statement on clinical research in the UKCarol Black, Andy Adam, Sabaratnam Arulkumaran, et al.
British Journal of Haematology|November 24, 2016
A United Kingdom Immune Thrombocytopenia (ITP) Forum review of practice: thrombopoietin receptor agonistsJecko Thachil, Catherine Bagot, Charlotte Bradbury, et al.
Blood|January 31, 2013
Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working GroupFrancesco Rodeghiero, Marc Michel, Terry Gernsheimer, et al.
Lancet (London, England)|February 5, 2008
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trialDavid J Kuter, James B Bussel, Roger M Lyons, et al.
Pageof 5